Kim Kyung-Jin, Yoon Junghan, Won Kyung Heon, Lim Sang-Wook, Chae In-Ho, Lee Sung Yun, Kim Sang-Wook, Kim Hyo-Soo
Division of Cardiology, Department of Internal Medicine, Ewha Womans University Medical Center, Ewha Womans University School of Medicine, Seoul 07985, Korea.
Division of Cardiology, Department of Internal Medicine, Yonsei University, Wonju Severance Christian Hospital, Wonju 26426, Korea.
J Clin Med. 2020 Mar 27;9(4):916. doi: 10.3390/jcm9040916.
The American College of Cardiology and American Heart Association (ACC/AHA) guidelines identified four statin benefit groups on the basis of atherosclerotic cardiovascular disease risk reduction and proposed statin therapy by evidence-based intensity. Although these guidelines used randomized controlled trials with hard outcomes as exclusive evidence for its recommendations, a limited number of studies conducted in Asian countries makes its application of treatment strategy, intensity, and statin doses uncertain in these population. This prospective, multicenter study aimed to evaluate the efficacy of rosuvastatin 10 mg in the four statin benefit groups requiring high- or moderate-intensity statin therapy according to the ACC/AHA guidelines in the Korean population. The primary endpoint was percentage reduction in low-density lipoprotein (LDL) cholesterol. Secondary endpoints were percentage reduction in other lipids and achievement of ≥50% reduction in LDL cholesterol. Rosuvastatin 10 mg lowered LDL cholesterol by 61.4 mg/dL, a 44.9% decrease from baseline after eight weeks. Reduction of LDL cholesterol ≥50% was achieved in 46.3% of patients. Rosuvastatin 10 mg was generally well tolerated. In the Korean population, rosuvastatin 10 mg was favorable and tolerant in lowering LDL cholesterol in the four statin benefit groups requiring high- or moderate-intensity statin therapy according to the ACC/AHA guidelines.
美国心脏病学会和美国心脏协会（ACC/AHA）指南根据动脉粥样硬化性心血管疾病风险降低情况确定了四个他汀类药物受益组，并根据循证强度推荐了他汀类药物治疗方案。尽管这些指南将具有硬终点的随机对照试验作为其推荐的唯一证据，但在亚洲国家进行的研究数量有限，使得这些人群的治疗策略、强度和他汀类药物剂量的应用尚不确定。这项前瞻性多中心研究旨在评估根据ACC/AHA指南，瑞舒伐他汀10毫克在韩国人群中四个需要高强度或中等强度他汀类药物治疗的受益组中的疗效。主要终点是低密度脂蛋白（LDL）胆固醇降低的百分比。次要终点是其他血脂降低的百分比以及LDL胆固醇降低≥50%。瑞舒伐他汀10毫克使LDL胆固醇降低了61.4毫克/分升，八周后较基线水平下降了44.9%。46.3%的患者实现了LDL胆固醇降低≥50%。瑞舒伐他汀10毫克总体耐受性良好。在韩国人群中，根据ACC/AHA指南，瑞舒伐他汀10毫克在四个需要高强度或中等强度他汀类药物治疗的受益组中降低LDL胆固醇方面效果良好且耐受性佳。
